Free Trial

Waters (WAT) Competitors

Waters logo
$452.74 -7.51 (-1.63%)
Closing price 03:59 PM Eastern
Extended Trading
$449.89 -2.85 (-0.63%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

WAT vs. BRKR, RGEN, TECH, A, and DHR

Should you buy Waters stock or one of its competitors? Waters's main competitors and comparable companies include Bruker (BRKR), Repligen (RGEN), Bio-Techne (TECH), Agilent Technologies (A), and Danaher (DHR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Waters compare to Bruker?

Waters (NYSE:WAT) and Bruker (NASDAQ:BRKR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Waters has a net margin of 1.75% compared to Bruker's net margin of -3.82%. Bruker's return on equity of 13.76% beat Waters' return on equity.

Company Net Margins Return on Equity Return on Assets
Waters1.75% 9.91% 6.11%
Bruker -3.82%13.76%5.47%

Waters presently has a consensus price target of $475.48, indicating a potential upside of 3.32%. Bruker has a consensus price target of $60.57, indicating a potential downside of 1.65%. Given Waters' stronger consensus rating and higher possible upside, equities analysts clearly believe Waters is more favorable than Bruker.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Waters
0 Sell rating(s)
6 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.79
Bruker
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
2.57

In the previous week, Waters had 17 more articles in the media than Bruker. MarketBeat recorded 19 mentions for Waters and 2 mentions for Bruker. Bruker's average media sentiment score of 0.80 beat Waters' score of 0.36 indicating that Bruker is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Waters
5 Very Positive mention(s)
0 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Bruker
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Waters has higher earnings, but lower revenue than Bruker. Bruker is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$3.17B14.29$642.63M$2.33197.51
Bruker$3.44B2.74-$8.60M-$1.10N/A

94.0% of Waters shares are owned by institutional investors. Comparatively, 79.5% of Bruker shares are owned by institutional investors. 0.3% of Waters shares are owned by insiders. Comparatively, 27.2% of Bruker shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Waters has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Bruker has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Summary

Waters beats Bruker on 11 of the 17 factors compared between the two stocks.

How does Waters compare to Repligen?

Waters (NYSE:WAT) and Repligen (NASDAQ:RGEN) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Waters has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$3.17B14.29$642.63M$2.33197.51
Repligen$738.26M14.53$48.89M-$0.21N/A

Waters presently has a consensus target price of $475.48, suggesting a potential upside of 3.32%. Repligen has a consensus target price of $178.57, suggesting a potential upside of 6.43%. Given Repligen's stronger consensus rating and higher probable upside, analysts clearly believe Repligen is more favorable than Waters.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Waters
0 Sell rating(s)
6 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.79
Repligen
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
2.83

Waters has a net margin of 1.75% compared to Repligen's net margin of -1.47%. Waters' return on equity of 9.91% beat Repligen's return on equity.

Company Net Margins Return on Equity Return on Assets
Waters1.75% 9.91% 6.11%
Repligen -1.47%5.49%3.93%

In the previous week, Waters had 15 more articles in the media than Repligen. MarketBeat recorded 19 mentions for Waters and 4 mentions for Repligen. Repligen's average media sentiment score of 1.00 beat Waters' score of 0.36 indicating that Repligen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Waters
5 Very Positive mention(s)
0 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Repligen
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Waters has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Repligen has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

94.0% of Waters shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 0.3% of Waters shares are held by company insiders. Comparatively, 0.6% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Waters beats Repligen on 10 of the 17 factors compared between the two stocks.

How does Waters compare to Bio-Techne?

Waters (NYSE:WAT) and Bio-Techne (NASDAQ:TECH) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Waters has higher revenue and earnings than Bio-Techne. Bio-Techne is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$3.17B14.29$642.63M$2.33197.51
Bio-Techne$1.22B9.41$181.86M$1.0966.79

In the previous week, Waters had 12 more articles in the media than Bio-Techne. MarketBeat recorded 19 mentions for Waters and 7 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.14 beat Waters' score of 0.36 indicating that Bio-Techne is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Waters
5 Very Positive mention(s)
0 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Bio-Techne
2 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

94.0% of Waters shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 0.3% of Waters shares are owned by insiders. Comparatively, 1.3% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bio-Techne has a net margin of 13.95% compared to Waters' net margin of 1.75%. Bio-Techne's return on equity of 13.00% beat Waters' return on equity.

Company Net Margins Return on Equity Return on Assets
Waters1.75% 9.91% 6.11%
Bio-Techne 13.95%13.00%10.57%

Waters presently has a consensus price target of $475.48, indicating a potential upside of 3.32%. Bio-Techne has a consensus price target of $68.92, indicating a potential downside of 5.33%. Given Waters' stronger consensus rating and higher possible upside, research analysts plainly believe Waters is more favorable than Bio-Techne.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Waters
0 Sell rating(s)
6 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.79
Bio-Techne
1 Sell rating(s)
14 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.12

Waters has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

Summary

Waters beats Bio-Techne on 9 of the 16 factors compared between the two stocks.

How does Waters compare to Agilent Technologies?

Waters (NYSE:WAT) and Agilent Technologies (NYSE:A) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

In the previous week, Waters had 9 more articles in the media than Agilent Technologies. MarketBeat recorded 19 mentions for Waters and 10 mentions for Agilent Technologies. Agilent Technologies' average media sentiment score of 0.46 beat Waters' score of 0.36 indicating that Agilent Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Waters
5 Very Positive mention(s)
0 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Agilent Technologies
6 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Agilent Technologies has higher revenue and earnings than Waters. Agilent Technologies is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$3.17B14.29$642.63M$2.33197.51
Agilent Technologies$7.37B6.65$1.30B$5.0834.25

94.0% of Waters shares are held by institutional investors. Comparatively, 87.4% of Agilent Technologies shares are held by institutional investors. 0.3% of Waters shares are held by insiders. Comparatively, 0.2% of Agilent Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Agilent Technologies has a net margin of 19.53% compared to Waters' net margin of 1.75%. Agilent Technologies' return on equity of 24.45% beat Waters' return on equity.

Company Net Margins Return on Equity Return on Assets
Waters1.75% 9.91% 6.11%
Agilent Technologies 19.53%24.45%13.09%

Waters has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

Waters presently has a consensus price target of $475.48, suggesting a potential upside of 3.32%. Agilent Technologies has a consensus price target of $181.45, suggesting a potential upside of 4.29%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Agilent Technologies is more favorable than Waters.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Waters
0 Sell rating(s)
6 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.79
Agilent Technologies
0 Sell rating(s)
4 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.82

Summary

Agilent Technologies beats Waters on 11 of the 17 factors compared between the two stocks.

How does Waters compare to Danaher?

Waters (NYSE:WAT) and Danaher (NYSE:DHR) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

94.0% of Waters shares are held by institutional investors. Comparatively, 79.1% of Danaher shares are held by institutional investors. 0.3% of Waters shares are held by company insiders. Comparatively, 10.8% of Danaher shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Danaher had 5 more articles in the media than Waters. MarketBeat recorded 24 mentions for Danaher and 19 mentions for Waters. Danaher's average media sentiment score of 1.33 beat Waters' score of 0.36 indicating that Danaher is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Waters
5 Very Positive mention(s)
0 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Danaher
19 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Waters presently has a consensus price target of $475.48, suggesting a potential upside of 3.32%. Danaher has a consensus price target of $242.91, suggesting a potential upside of 4.18%. Given Danaher's higher possible upside, analysts clearly believe Danaher is more favorable than Waters.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Waters
0 Sell rating(s)
6 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.79
Danaher
0 Sell rating(s)
5 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.78

Danaher has higher revenue and earnings than Waters. Danaher is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$3.17B14.29$642.63M$2.33197.51
Danaher$24.57B6.68$3.61B$6.1138.16

Waters has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Danaher has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Danaher has a net margin of 16.91% compared to Waters' net margin of 1.75%. Danaher's return on equity of 11.17% beat Waters' return on equity.

Company Net Margins Return on Equity Return on Assets
Waters1.75% 9.91% 6.11%
Danaher 16.91%11.17%6.71%

Summary

Danaher beats Waters on 11 of the 17 factors compared between the two stocks.

Get Waters News Delivered to You Automatically

Sign up to receive the latest news and ratings for WAT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WAT vs. The Competition

MetricWatersLife Sciences Tools & Services IndustryHealthcare SectorNYSE Exchange
Market Cap$44.50B$10.83B$7.83B$23.18B
Dividend YieldN/A1.45%2.47%3.78%
P/E Ratio194.3151.4934.3229.41
Price / Sales7.937.118.003.24
Price / Cash27.6826.7921.0215.64
Price / Book10.535.804.764.04
Net Income$642.63M$57.47B$3.52B$1.08B
7 Day Performance-5.11%-5.43%-5.35%-3.09%
1 Month Performance3.63%-0.97%-3.62%-1.21%
1 Year Performance19.19%18.51%-0.62%5.64%

Waters Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WAT
Waters
2.2872 of 5 stars
$452.74
-1.6%
$475.48
+5.0%
+21.1%$44.50B$5.61B194.317,900
BRKR
Bruker
2.4639 of 5 stars
$66.54
+8.5%
$60.57
-9.0%
+48.0%$9.72B$3.44BN/A11,085
RGEN
Repligen
2.7568 of 5 stars
$178.94
+3.1%
$178.57
-0.2%
+10.1%$11.39B$738.26M87.352,000
TECH
Bio-Techne
2.1735 of 5 stars
$72.83
+0.1%
$68.92
-5.4%
+22.6%$11.42B$1.22B42.283,000
A
Agilent Technologies
3.7705 of 5 stars
$180.09
+3.0%
$181.45
+0.8%
+18.4%$49.95B$6.95B29.2418,100

Related Companies and Tools


This page (NYSE:WAT) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners